SCHEMBL3621657

SCHEMBL3621657

CCN(c1cc(N2CCCNCC2)ccc1NS(=O)(=O)c1ccc2cccnc2c1)S(C)(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 13/20 0.40
HTR7 P34969 5/20 0.40
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
RAD52 P43351 1/20 0.38
HTR1A P08908 4/20 0.36
HTR2A P28223 4/20 0.36
DRD2 P14416 2/20 0.36
HTR1D P28221 2/20 0.36
HTR1B P28222 2/20 0.36
DRD3 P35462 1/20 0.36
NMT1 P30419 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNA4 P43681 1/20 0.36
MEN1 O00255 1/20 0.35
AGTR1 P30556 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5067258 0.99 HTR6 (0.41) HTR6HTR7OPRM1OPRD1OPRK1
Hydrochloric Acid SCHEMBL3621795 0.84 GFER (0.49) HTR6HTR7MEN1KMT2A
SCHEMBL3622419 0.83 ALDH1A1 (0.44) HTR6NMT1MEN1KMT2A
Hydrochloric Acid SCHEMBL3622903 0.83 ALDH1A1 (0.43) HTR6RAD52NMT1MEN1KMT2A
SCHEMBL3618018 0.81 HCRTR1 (0.49) HTR6HTR7HTR1A
Hydrochloric Acid SCHEMBL3621152 0.81 HCRTR1 (0.49) HTR6HTR7HTR1A
Hydrochloric Acid SCHEMBL6858076 0.78 HTR6 (0.48) HTR6HTR7HTR1A
Hydrochloric Acid SCHEMBL6860702 0.78 RAD52 (0.47) HTR6HTR7RAD52HTR1AHTR2A
SCHEMBL3616826 0.77 HTR6 (0.50) HTR6
Hydrochloric Acid SCHEMBL3625041 0.77 RAD52 (0.53) HTR6HTR7RAD52HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718650-B2 Aryl sulfonamide compounds for treating obesity BIOVITRUM AB (SE) 2010-05-18 US disclosed
US-7566715-B2 Substituted sulfonamide compounds useful for the prophylaxis and treatment of conditions relating to obesity, type II diabetes and/or disorders of the central nervous system BIOVITRUM AB (SE) 2009-07-28 US disclosed
US-20080096873-A1 NEW COMPOUNDS BIOVITRUM AB, A SWEDEN CORPORATION 2008-04-24 US disclosed
US-7319097-B2 Treatment of type II diabetes with benzenesulfonamide substituted with an N-heterocycle: N-[2-amino-5-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide, N-[4-amino-5-(piperazinyl)phenyl]benzenesulfonamide, 3-amino-4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-N-phenyl-benzenesulfonamide hydrochloride BIOVITRUM AB (SE) 2008-01-15 US disclosed
US-7173035-B2 Arylsulfonamide compounds BIOVITRUM AB (SE) 2007-02-06 US disclosed
US-20060009446-A1 New compounds BIOVITRUM AB, A SWEDEN CORPORATION 2006-01-12 US disclosed
US-6969710-B2 Compounds BIOVITRUM AB (SE) 2005-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009446-A1 New compounds GPR119, SULT2A1, STS HTR6 484/4885HTR7 1150/4885OPRM1 687/4885
US-20080096873-A1 NEW COMPOUNDS GPR119, SULT2A1, STS HTR6 484/4885HTR7 1150/4885OPRM1 687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.